Oncotype DX® Breast Recurrent Score Financial Assistance Programme

Self Photos / Files - Logo

 

What is the Breast Recurrence Score Financial Assistance Programme?

The Breast Recurrence Score Financial Assistance Programme is designed to help alleviate the financial burden for patients residing in Hong Kong who have recently received surgery to remove their breast tumor within the public health system managed by the Hospital Authority, as a public-care patient. Clinically eligible and means-tested patients may receive the Oncotype DX ® Breast Recurrence Score test at subsidized rates to find out definitively whether or not they can benefit from chemotherapy based on their Breast Recurrence Score results.

 

What is the Oncotype DX Breast Recurrence Score Test?

This is a genomic test performed on a patient’s breast tumor tissue to provide personalized information to help understand whether adding chemotherapy to her treatment regimen is likely to be beneficial.  The tumor specimen is sent to Genomic Health in the USA for testing.

 

What does the Breast Recurrence Score result mean to your treatment decision?

You and your physician will use your individual Recurrence Score result to more accurately assess the likely benefit of chemotherapy. Patients with node-negative disease and a Recurrence Score result of 26 to 100 will have substantial benefit from the addition of chemotherapy to hormone therapy. In the vast majority of patients with a Recurrence Score result of 0 to 25, adding chemotherapy will not reduce this risk. Your physician will use the test result to tailor the appropriate treatment plan for you.

 

Who can benefit from the Oncotype DX® test?

Patients who are recently diagnosed with an early stage invasive breast cancer that is hormone receptor-positive, HER2-negative, lymph node-negative, and where appropriate as advised by your physician, involving up to 3 positive lymph nodes.

 

Who can qualify for the programme?

Qualified applicants must be HKSAR permanent residents and fulfill all the criteria below:

 

Patients who:

  • Were newly diagnosed with early stage invasive breast cancer and meet all of following clinical requirements:
    • node-negative or node-positive (1-3 lymph nodes), and
    • hormone receptor-positive (HR+) and
    • HER2-negative
  • Received breast tumor surgery as a public-care patient and the Oncotype DX® Breast Recurrence Score test was recommended by registered doctor in public hospital of Hospital Authority, HKSAR.
  • Met the financial assessment criteria:
Average Monthly Individual Income in the past 12 months

Amount of Financial Assistance

(Subsidy of Oncotype DX® Test Fee)

Between HK$17,401 - HK$26,100

Half

HK$17,400 or below / Comprehensive Social Security Assistance (CSSA)

Full

 

Documents Required for Application

Original copy of:

  1. Completed  Oncotype DX® Breast Recurrent Score Financial Assistance Programme Application Form
  2.  Doctor's referral letter for Oncotype DX® Breast Recurrent Score Financial Assistance Programme

Photocopy of:

  1. HKSAR identity card
  2. Financial proof of individual income

 

Application Procedure

Please fill in the  application form which can be downloaded from www.hkbcf.org or obtain in person at Hong Kong Breast Cancer Foundation (HKBCF) Breast Cancer Support Centre at:

 

Hong Kong

22/F., Jupiter Tower, 9 Jupiter Street, North Point, Hong Kong

Kowloon

28 Lung Cheung Road, Ngau Chi Wan, Kowloon

 

Office hour from Monday to Saturday:

9:10am-1:00pm and 2:00pm-6:00pm

 

Tel: 2525 6033

 

Applicants are required to submit the application form along with all supporting documents to the HKBCF in person at Breast Cancer Support Centre.

(Please remark "ATTN: Breast Recurrence Score Financial Assistance Programme" on the envelope.)

 

Qualified applicants will receive a confirmation letter from the HKBCF within 5 working days.

 

Sponsorship Arrangement

Qualified applicants with partial subsidy will be provided further information regarding payment of the remaining test fee upon confirmation.

Qualified applicants with full subsidy will be notified once the Oncotype DX® Breast Recurrence Score test is successfully ordered.

 

Report will be sent to applicants' doctors-in-charge.

 

Remarks:

  • Applicants should read the leaflet of Oncotype DX® Breast Recurrent Score Financial Assistance Programme and the application form carefully to determine whether they are qualified to join the Programme before submission.
  • This Programme is for individual patient only and is not intended for clinics or hospitals.
  • HKBCF may request further information and supporting documents from applicants for financial assessment purposes. HKBCF may also request to interview applicants and household members, make home visits and contact applicants' doctors-in-charge for more information.
  • All personal information collected will be treated in strictest confidence and in accordance to the Personal Data (Privacy) Ordinance.
  • HKBCF shall assess all applications and reserves the right for making the final decision to approve an application.
  • HKBCF reserves the rights for declining an application or terminating the Financial Assistance Programme without advance notice.